<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">SARS-CoV-2 is a positive-sense RNA virus. The only positive-sense RNA virus, for which a very effective drug targeting specifically the RdRp is available and approved world-wide for clinical use, is hepatitis C virus (HCV). In the specific, Sofosbuvir (Sovaldi®; Epclusa® by Gilead) is a direct antiviral agent (DAA) that inhibits the hepatitis C NS5B RdRp protein [
 <xref ref-type="bibr" rid="CR13">13</xref>]. Interestingly, it has been already shown to be effective in vitro and in humans for other two different positive-sense RNA viruses, namely Yellow Fever and Hepatitis A virus [
 <xref ref-type="bibr" rid="CR14">14</xref>, 
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
